Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Non-Current Deffered Revenue (2022 - 2023)

Capricor Therapeutics (CAPR) has 4 years of Non-Current Deffered Revenue data on record, last reported at $953470.0 in Q3 2023.

  • For Q3 2023, Non-Current Deffered Revenue fell 90.27% year-over-year to $953470.0; the TTM value through Sep 2023 reached $953470.0, down 90.27%, while the annual FY2022 figure was $9.5 million, N/A changed from the prior year.
  • Non-Current Deffered Revenue reached $953470.0 in Q3 2023 per CAPR's latest filing, down from $3.2 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $20.3 million in Q1 2022 and bottomed at $953470.0 in Q3 2023.